Sipuleucel-T is a personalized therapy, made from patient’s peripheral blood mononuclear cells incubated with a fusion protein consisting of a common prostate cancer antigen (prostatic acid phosphatase) linked to an adjuvant (granulocyte–macrophage colony-stimulating factor). This evidence concerns the gene ACP3 and cancer.